ArticleJournal of hepatocellular carcinoma2024

Transarterial Chemoembolization Plus Camrelizumab and Rivoceranib versus Camrelizumab and Rivoceranib Alone for BCLC Stage C Hepatocellular Carcinoma.

Wen-Jie Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.